Neurochem Unblinds the Phase II/III Study for Fibrillex

Neurochem has unblinded the Phase II/III clinical study for its investigational product candidate, 1,3-propanedisulfonate (1,3PDS; Fibrillex) to treat Amyloid A amyloidosis.

Neurochem will release the results of the trial upon receipt, analysis and full validation of the unblinded data. Neurochem currently expects that this process will take approximately two weeks. Should the analysis and validation of the data require additional time, the company will advise the market accordingly.